Rowland Lloyd A (CIK 0001236395)

Latest company ownership

CTMX - CytomX Therapeutics, Inc.

Role: General Counsel

Shares held

120,594

Last filed at

Mar 20, 2025

Confidence Score

50.0

2025Q4

Confidence Score History

2019Q1 2025Q4

Recent buy/sell transactions

Exec date	Filing date	Company	Role	Signal	Confidence	Shares	% of shares	Under plan?	Amount (USD)
Mar 18, 2025	Mar 20, 2025	CytomX Therapeutics, Inc.	General Counsel	Sell	47.5	-10,203	-7.80%	✗	$6.1K
Aug 20, 2024	Aug 22, 2024	CytomX Therapeutics, Inc.	General Counsel	Sell	47.5	-4,181	-3.10%	✗	$5.1K
Mar 19, 2024	Mar 21, 2024	CytomX Therapeutics, Inc.	General Counsel	Sell	46.3	-5,268	-4.28%	✗	$11K
Dec 20, 2023	Dec 22, 2023	CytomX Therapeutics, Inc.	General Counsel	Sell	47.5	-4,077	-3.99%	✗	$5.6K
Sep 20, 2023	Sep 22, 2023	CytomX Therapeutics, Inc.	General Counsel	Sell	90.0	+9,514	13.38%	✗	$7.1K
Mar 16, 2023	Mar 20, 2023	CytomX Therapeutics, Inc.	General Counsel	Sell	47.5	-2,037	-2.79%	✗	$4K
Jul 19, 2022	Jul 21, 2022	CytomX Therapeutics, Inc.	General Counsel	Sell	90.0	+9,398	27.41%	✗	$8K
Mar 4, 2019	Mar 5, 2019	CytomX Therapeutics, Inc.	General Counsel	Buy	95.0	+9,000	919.31%	✗	$93K